Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Thrombosis and Haemostasis

• Publication date

  2016-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH15-10-0770PMID 27009446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up

  2015cited by this paper
• Association between statin use and plasma D-dimer levels

  2015cited by this paper
• The impact of statin therapy on plasma levels of von Willebrand factor antigen

  2015cited by this paper
• Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study.

  2015cited by this paper
• Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials.

  2015cited by this paper
• Association of inflammatory and hemostatic markers with stroke and thromboembolic events in atrial fibrillation: a systematic review and meta-analysis.

  2015cited by this paper
• Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: results from the ATHEROREMO-IVUS study.

  2014cited by this paper
• The antithrombotic effects of statins.

  2014cited by this paper
• Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Effect of Simvastatin on Hemostasis in Patients with Isolated Hypertriglyceridemia

  2013cited by this paper
• Association of a prothrombotic state with left-ventricular diastolic dysfunction in hypertension: a tissue-Doppler imaging study

  2013influential reference
• Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials

  2013cited by this paper
• The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia

  2012cited by this paper
• TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes.

  2012cited by this paper
• Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

  2012cited by this paper
• Effects of Atorvastatin on the Different Phases of Atherogenesis

  2012cited by this paper
• A prothrombotic state is associated with early arterial damage in hypertensive patients.

  2012influential reference
• Atherosclerosis: current pathogenesis and therapeutic options

  2011cited by this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes

  2010cited by this paper
• Regulation of the endothelial plasminogen activator system by fluvastatin

  2010cited by this paper
• Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.

  2010cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Supplementary webappendix

  2009cited by this paper
• Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects

  2009cited by this paper
• HMG‐CoA reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis

  2009cited by this paper
• Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.

  2009cited by this paper
• A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

  2009cited by this paper
• Effect of atorvastatin on endothelial function and inflammation in long‐duration type 1 diabetic patients without coronary heart disease and arterial hypertension

  2008cited by this paper
• Candidate Mechanisms for Regression of Coronary Atherosclerosis with High-Dose Statins

  2008cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.

  2007cited by this paper
• Effect of Fluvastatin and Valsartan, Alone and in Combination, on Postprandial Vascular Inflammation and Fibrinolytic Activity in Patients With Essential Hypertension

  2007cited by this paper
• New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a)

  2005cited by this paper
• Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation

  2004cited by this paper
• The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes.

  2004cited by this paper
• The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors

  2004cited by this paper
• Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus

  2003cited by this paper
• Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality

  2003cited by this paper
• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

  2003cited by this paper
• Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease

  2003cited by this paper
• Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial.

  2002cited by this paper
• Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity.

  2002cited by this paper
• Treatment of Dyslipidaemia with Fluvastatin in Patients with Type 2 Diabetes Mellitus

  2001cited by this paper
• Fluvastatin Decreases Soluble Thrombomodulin in Cardiac Transplant Recipients

  2000cited by this paper
• Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease.

  2000cited by this paper
• Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis

  2000cited by this paper
• Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.

  1999cited by this paper
• Plasminogen Activator Inhibitor-1 (PAI-1) Promoter 4G/5G Genotype and Increased PAI-1 Circulating Levels in Postmenopausal Women with Coronary Artery Disease

  1999cited by this paper
• Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.

  1999cited by this paper
• The 4G4G Genotype of the Plasminogen Activator Inhibitor 4G/5G Gene Polymorphism Is Associated with Coronary Atherosclerosis in Patients at High Risk for this Disease

  1999cited by this paper
• High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

  1998cited by this paper
• Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.

  1997cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.

  1995cited by this paper

• Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated LIPOPROTEIN(a)

  2025cites this paper
• Changes in fibrin clot properties in patients after Roux-en-Y gastric bypass surgery

  2024cites this paper
• Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications

  2024cites this paper
• Orchestra of ligand-activated transcription factors in the molecular symphony of SERPINE 1 / PAI-1 gene regulation.

  2024cites this paper
• Fibrinogen and plasma clot properties are associated with apolipoprotein B and apolipoprotein B-containing lipoproteins in Africans.

  2024cites this paper
• PAI-1 Regulates the Cytoskeleton and Intrinsic Stiffness of Vascular Smooth Muscle Cells

  2024cites this paper
• Beneficial effects of prehospital use of statins in a large United States cohort of hospitalized coronavirus disease 2019 patients

  2023cites this paper
• Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

  2023cites this paper
• Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients.

  2023cites this paper
• Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization

  2023cites this paper
• Rapid Regression of Carotid Artery Stenosis Shortly after Intensive Medical Therapy

  2022cites this paper
• Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors

  2022cites this paper
• Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19

  2022cites this paper
• Simvastatin Improves Outcomes of Endotoxin-induced Coagulopathy by Regulating Intestinal Microenvironment

  2022cites this paper
• Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out?

  2021cites this paper
• Atorvastatin Inhibits Endothelial PAI-1-Mediated Monocyte Migration and Alleviates Radiation-Induced Enteropathy

  2021cites this paper
• COVID-19: Direct and Indirect Mechanisms of Statins

  2021cites this paper
• Mesenchymal stromal cells-based therapy in a murine model of elastase-induced emphysema: simvastatin as a positive adjuvant in cellular homing.

  2021cites this paper
• COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection

  2021cites this paper
• Simvastatin improves the prognosis of endotoxin-induced disseminated intravascular coagulation by regulating the intestinal microenvironment

  2020cites this paper
• Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome.

  2020cites this paper
• The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review

  2020cites this paper
• Dietary natural products as emerging lipoprotein(a)‐lowering agents

  2019cites this paper
• Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review

  2019cites this paper
• Evaluation and Treatment of Atherogenic Dyslipidemia

  2018cites this paper
• Rosuvastatin- and Heparin-Loaded Poly(l-lactide- co-caprolactone) Nanofiber Aneurysm Stent Promotes Endothelialization via Vascular Endothelial Growth Factor Type A Modulation.

  2018cites this paper
• THE ADVANTAGES AND DISADVANTAGES OF STATIN THERAPY FOR DYSLIPIDEMIA

  2018cites this paper
• The effect of statin therapy on endoplasmic reticulum stress

  2018cites this paper
• Pre-Procedural Statin Use Is Associated with Improved Long-Term Survival and Reduced Major Cardiovascular Events in Patients Undergoing Carotid Artery Stenting: A Retrospective Study

  2018cites this paper
• Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal

  2018cites this paper
• Statins: pros and cons.

  2017cites this paper
• Statins, haemostatic factors and thrombotic risk

  2017cites this paper
• Optimization of monitoring and management of anticoagulant therapy

  2017cites this paper
• Short-term dietary interventions in persons with cardiovascular risk factors

  2017cites this paper
• Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

  2017cites this paper
• SYSTEMATIC REVIEW AND META – ANALYSIS Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis

  2017cites this paper
• eview tatins : pros and cons ago

  2017cites this paper
• Effect of ezetimibe on plasma adipokines: a systematic review and meta‐analysis

  2017cites this paper
• Statin Therapy Negatively Impacts Skeletal Muscle Regeneration and Cutaneous Wound Repair in Type 1 Diabetic Mice

  2017cites this paper
• Increased plasminogen activator inhibitor results in a hypofibrinolytic state in adolescents with obesity: in vivo and ex vivo evidence

  2016cites this paper
• Impact of statin therapy on plasma leptin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials.

  2016cites this paper
• Arteriosclerosis, Thrombosis, and Vascular Biology.

  2015cites this paper